City of Hope

Edward S. Kim, MD, MBA, and Neel Shah, MD, discuss advancing lung cancer care and tackling real-world access barriers for community physicians in the Treating Together podcast.

Michael Caligiuri, MD, discusses the modulation of natural killer cells to enhance their ability to detect and destroy tumor cells.

Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations.

Terence M. Williams, MD, PhD, discussed the phase 1 DINOMITE trial of radiation therapy and papaverine in rectal cancer at City of Hope.

Terence M. Williams, MD, PhD, discusses what inspired the new phase 1 DINOMITE trial at City of Hope.

David Craig, PhD, discusses how AI is transforming cancer histopathology.

Aditya Shreenivas, MD, MS, discusses the clinical trial that led to the FDA approval of penpulimab in nasopharyngeal carcinoma.

Aditya Shreenivas, MD, MS, discusses findings from the clinical trial supporting the FDA approval of penpulimab in nasopharyngeal carcinoma.

Amandeep Salhotra, MD, discusses data from the phase 3 Precision-T trial of Orca-T in patients with advanced hematologic malignancies.

Amandeep Salhotra, MD, discusses Orca-T and its evaluation in the phase 3 Precision-T trial in patients with advanced hematologic malignancies.

Anthony S. Stein, MD, discusses a study of total marrow and lymphoid irradiation 20 Gy and post-transplant cyclophosphamide in acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients.

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

The biorepository will aggregate critical information about City of Hope’s national patient population to expand research capacity across a wide range of diseases

Regina Barragan-Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with renal cell carcinoma.

Alan H. Bryce, MD, discusses ongoing research in radioligand therapies.

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with acute myeloid leukemia.

Geoffrey Shouse, DO, PhD, discusses the growing interest in bispecific antibodies within the field of oncology.

Marwan G. Fakih, MD, discusses the next steps for the clinical development of the balstilimab plus botensilimab in microsatellite stable metastatic colorectal cancer without liver metastases.

In an interview, Regina Barragan-Carrillo, MD, highlighted the ongoing global disparities in renal cell carcinoma clinical trials.

Colton Ladbury, MD, discusses radiation therapy for hematologic malignancies, total marrow irradiation, and findings that were presented during the American Society for Radiation Oncology Annual Meeting.

The California wildfires severely affected patients with cancer, requiring evacuation protocols, community support, and learning for future disaster preparedness.

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.

William Dale, MD, PhD, FASCO, highlighted the shift from the first geriatric oncology guidelines made in 2018 to the advancements that are shaping the field today.

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver metastases.

Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for the treatment of patients with microsatellite stable metastatic colorectal cancer without liver metastases.

Marwan G. Fakih, MD, provides an overview of the study design, rationale, and findings from a phase 2 trial of balstilimab with botensilimab for the treatment of patients with microsatellite stable metastatic colorectal cancer without liver metastases.

Ajay Goel, PhD, AGAF, discusses how the development and validation of novel non-invasive biomarkers can improve early detection and ultimately impact patient outcomes for patients.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.